Eisai released a simulation forecasting Leqembi sales near JPY 300 billion for fiscal year 2028. BioArctic outlines approvals, regulatory progress, and ongoing clinical programs tied to lecanemab.
Key Takeaways
- Leqembi is approved in 53 countries and under regulatory review in 6 countries.